Skip to main content

Main menu

  • Home
  • Articles
    • Current issue
    • ERJ Early View
    • Archive
  • About
    • About continuous publication
    • Journal information
    • Editorial Board
    • CME
    • Press office
    • Permissions and reprints
    • Advertising
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS author centre
  • For readers
    • Alerts
    • Subjects
    • Podcasts
    • RSS
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Articles
    • Current issue
    • ERJ Early View
    • Archive
  • About
    • About continuous publication
    • Journal information
    • Editorial Board
    • CME
    • Press office
    • Permissions and reprints
    • Advertising
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • ERS author centre
  • For readers
    • Alerts
    • Subjects
    • Podcasts
    • RSS
  • Subscriptions

Effect of roflumilast in patients with severe COPD and a history of hospitalisation

Klaus F. Rabe, Peter M.A. Calverley, Fernando J. Martinez, Leonardo M. Fabbri
European Respiratory Journal 2017 50: 1700158; DOI: 10.1183/13993003.00158-2017
Klaus F. Rabe
LungenClinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, GermanyCo-primary authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kfrabe@lungenclinic.de
Peter M.A. Calverley
Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UKCo-primary authors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando J. Martinez
Weill Cornell Medical College, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leonardo M. Fabbri
University of Modena and Reggio Emilia, Modena, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Leonardo M. Fabbri
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Extract

Exacerbations of chronic obstructive pulmonary disease (COPD) are acute events characterised by a worsening of respiratory symptoms that necessitates a change in medication and/or hospital admission [1]. Severe exacerbations (those resulting in hospitalisation and/or death) are associated with a poor prognosis [2], decreased quality of life [3] and higher mortality [2, 4]. Roflumilast is a once-daily, oral, selective phosphodiesterase-4 inhibitor that targets both the systemic and pulmonary inflammation associated with COPD [5]. Previous studies have shown that roflumilast as an add-on to inhaled therapies reduces COPD exacerbations in patients with severe COPD who have chronic bronchitis and a history of exacerbations [6–9]. However, the adverse events associated with systemic therapies such as roflumilast necessitate that these therapies are used to treat specific patient populations in whom they are likely to have the greatest clinical benefit [10].

Abstract

Roflumilast provides greater therapeutic benefit in severe COPD patients with a hospitalisation in the prior year http://ow.ly/lzWy30bNBd4

Acknowledgements

We thank Alexis Pashiardis (Synergy Vision, London, UK; supported by AstraZeneca) for writing and editorial assistance with the preparation of this research letter. These results were presented at the European Respiratory Society International Congress in 2015.

Footnotes

  • Clinical trial: This study is registered with clinicaltrials.gov with the identifier NCT01329029.

  • Support statement: This study was funded by Takeda Pharmaceutical Company and AstraZeneca. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

  • Received January 23, 2017.
  • Accepted March 29, 2017.
  • Copyright ©ERS 2017
View Full Text

INDIVIDUALS

Log in using your username and password

– ERS members: log in with your myERS username and password.
– Other users: log in with the credentials you created when you registered.
Forgot your user name or password?
Forgot your username or password?

PURCHASE SHORT TERM ACCESS

Purchase access - gain access to this article from US$15.00

Regain Access - You can regain access to a recently purchased content if the access period has not yet expired.

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email info@ersj.org.uk

CONTACT US

If you have any questions about the ERS publications website, please contact info@ersj.org.uk

PreviousNext
Back to top
View this article with LENS
Vol 50 Issue 1 Table of Contents
European Respiratory Journal: 50 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effect of roflumilast in patients with severe COPD and a history of hospitalisation
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Effect of roflumilast in patients with severe COPD and a history of hospitalisation
Klaus F. Rabe, Peter M.A. Calverley, Fernando J. Martinez, Leonardo M. Fabbri
European Respiratory Journal Jul 2017, 50 (1) 1700158; DOI: 10.1183/13993003.00158-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Effect of roflumilast in patients with severe COPD and a history of hospitalisation
Klaus F. Rabe, Peter M.A. Calverley, Fernando J. Martinez, Leonardo M. Fabbri
European Respiratory Journal Jul 2017, 50 (1) 1700158; DOI: 10.1183/13993003.00158-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Disclosures
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Role of a clinical prediction score in a CTEPH rule-out strategy
  • Evaluation of VTE-BLEED for predicting intracranial or fatal bleeding in VTE patients
  • Cyclophosphamide in steroid refractory unclassifiable IIP and IPAF
Show more 3

Research letters

  • Role of a clinical prediction score in a CTEPH rule-out strategy
  • Evaluation of VTE-BLEED for predicting intracranial or fatal bleeding in VTE patients
  • Cyclophosphamide in steroid refractory unclassifiable IIP and IPAF
Show more 3

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Collections
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Fax: +44 114 266 5064
Email: info@ersj.org.uk

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2018 by the European Respiratory Society